Experimental cell combo for tough breast cancer halted after just 2 patients
NCT ID NCT05385705
First seen Nov 01, 2025 · Last updated May 25, 2026 · Updated 23 times
Summary
This early-phase study tested whether adding donor natural killer (NK) cells to standard antibody drugs (trastuzumab and pertuzumab) could help people with advanced HER2-positive breast cancer that had stopped responding to other treatments. Only 2 participants were enrolled before the study was terminated, so no conclusions about effectiveness can be drawn. The main goal was to check safety and tolerability.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST NEOPLASMS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Hospital del Mar
Barcelona, 08003, Spain
-
Vall d'Hebron Hospital
Barcelona, 08035, Spain
Conditions
Explore the condition pages connected to this study.